{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T17:39:11Z","timestamp":1781285951042,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s11523-023-00990-6","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T09:02:22Z","timestamp":1694163742000},"page":"735-747","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients"],"prefix":"10.1007","volume":"18","author":[{"given":"Scott","family":"Jew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Bujarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Regidor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marsiye","family":"Emamy-Sadr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Swift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Eades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrooz","family":"Eshaghian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1587-6104","authenticated-orcid":false,"given":"James R.","family":"Berenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"key":"990_CR1","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2147\/CIA.S89465","volume":"11","author":"J Willan","year":"2016","unstructured":"Willan J, Eyre TA, Sharpley F, Watson C, King AJ, Ramasamy K. Multiple myeloma in the very elderly patient: challenges and solutions. Clin Interv Aging. 2016;11:423\u201335. https:\/\/doi.org\/10.2147\/CIA.S89465.","journal-title":"Clin Interv Aging"},{"issue":"3","key":"990_CR2","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","volume":"36","author":"M Binder","year":"2022","unstructured":"Binder M, Nandakumar B, Rajkumar SV, Kapoor P, Buadi FK, Dingli D, et al. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia. 2022;36(3):801\u20138. https:\/\/doi.org\/10.1038\/s41375-021-01453-5.","journal-title":"Leukemia"},{"issue":"15","key":"990_CR3","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2015","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blad\u00e9 J, et al. International staging system for multiple myeloma. J Clin Oncol. 2015;23(15):3412\u201320. https:\/\/doi.org\/10.1200\/JCO.2005.04.242.","journal-title":"J Clin Oncol"},{"issue":"26","key":"990_CR4","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863\u20139. https:\/\/doi.org\/10.1200\/JCO.2015.61.2267.","journal-title":"J Clin Oncol"},{"issue":"1","key":"990_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13045-021-01162-7","volume":"14","author":"CT Wallington-Beddoe","year":"2021","unstructured":"Wallington-Beddoe CT, Mynott RL. Prognostic and predictive biomarker developments in multiple myeloma. J Hematol Oncol. 2021;14(1):151. https:\/\/doi.org\/10.1186\/s13045-021-01162-7.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"990_CR6","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u201348. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5.","journal-title":"Lancet Oncol"},{"issue":"8","key":"990_CR7","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6.","journal-title":"Lancet Oncol"},{"issue":"2","key":"990_CR8","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41375-018-0272-0","volume":"33","author":"TW Klausen","year":"2019","unstructured":"Klausen TW, Gregersen H, Abildgaard N, Andersen NF, Fr\u00f8lund UC, Gimsing P, et al. The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials. Leukemia. 2019;33(2):546\u20139. https:\/\/doi.org\/10.1038\/s41375-018-0272-0.","journal-title":"Leukemia"},{"issue":"9","key":"990_CR9","doi-asserted-by":"publisher","first-page":"e363","DOI":"10.1016\/j.clml.2018.06.008","volume":"18","author":"MK Malecek","year":"2018","unstructured":"Malecek MK, Fiala M, Schroeder M, Dukeman J, Ghobadi A, Stockerl-Goldstein K, et al. Multiple myeloma patients ineligible for randomized controlled trials have poorer outcomes irrespective of treatment. Clin Lymphoma Myeloma Leuk. 2018;18(9):e363\u20134. https:\/\/doi.org\/10.1016\/j.clml.2018.06.008.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"990_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208507","volume":"13","author":"K Remes","year":"2018","unstructured":"Remes K, Anttila P, Silvennoinen R, Putkonen M, Ollikainen H, Ter\u00e4v\u00e4 V, et al. Real-world treatment outcomes in multiple myeloma: multicenter registry results from Finland 2009\u20132013. PLoS ONE. 2018;13(12): e0208507. https:\/\/doi.org\/10.1371\/journal.pone.0208507.","journal-title":"PLoS ONE"},{"issue":"7","key":"990_CR11","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/nar\/22.7.1147","volume":"22","author":"Y Laabi","year":"1994","unstructured":"Laabi Y, Gras MP, Brouet JC, Berger R, Larsen CJ, Tsapis A. The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed. Nucleic Acids Res. 1994;22(7):1147\u201354. https:\/\/doi.org\/10.1093\/nar\/22.7.1147.","journal-title":"Nucleic Acids Res"},{"key":"990_CR12","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","volume":"16","author":"SA Laurent","year":"2015","unstructured":"Laurent SA, Hoffmann FS, Kuhn PH, Cheng Q, Chu Y, Schmidt-Supprian M, et al. \u03b3-secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun. 2015;16:7333. https:\/\/doi.org\/10.1038\/ncomms8333.","journal-title":"Nat Commun"},{"issue":"4","key":"990_CR13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s11523-021-00821-6","volume":"16","author":"S Bujarski","year":"2021","unstructured":"Bujarski S, Udd K, Soof C, Chen H, Spektor TM, Safaie T, et al. Baseline and changes in serum B-cell maturation antigen levels rapidly indicate changes in clinical status among patients with relapsed\/refractory multiple myeloma starting new therapy. Target Oncol. 2021;16(4):503\u201315. https:\/\/doi.org\/10.1007\/s11523-021-00821-6.","journal-title":"Target Oncol"},{"issue":"2","key":"990_CR14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/hon.2961","volume":"40","author":"S Bujarski","year":"2022","unstructured":"Bujarski S, Sutanto C, Spektor TM, To J, Swift RA, Green T, et al. Use of serum B-cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone. Hematol Oncol. 2022;40(2):243\u20138. https:\/\/doi.org\/10.1002\/hon.2961.","journal-title":"Hematol Oncol"},{"issue":"4","key":"990_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/14737159.2018.1448269","volume":"18","author":"E Sanchez","year":"2018","unstructured":"Sanchez E, Tanenbaum EJ, Patil S, Li M, Soof CM, Vidisheva A, et al. The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker. Expert Rev Mol Diagn. 2018;18(4):319\u201329. https:\/\/doi.org\/10.1080\/14737159.2018.1448269.","journal-title":"Expert Rev Mol Diagn"},{"key":"990_CR16","unstructured":"QuickFacts California. United States Census Bureau. 2023. https:\/\/www.census.gov\/quickfacts\/CA. Accessed May 26, 2022"},{"issue":"5","key":"990_CR17","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/j.1365-2141.2011.08884.x","volume":"155","author":"JR Berenson","year":"2011","unstructured":"Berenson JR, Yellin O, Chen CS, Patel R, Bessudo A, Boccia RV, et al. A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients. Br J Haematol. 2011;155(5):580\u20137. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08884.x.","journal-title":"Br J Haematol"},{"issue":"6","key":"990_CR18","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1111\/bjh.16673","volume":"192","author":"S Jew","year":"2021","unstructured":"Jew S, Bujarski S, Soof C, Chen H, Safaie T, Li M, et al. Estimating a normal reference range for serum B-cell maturation antigen levels for multiple myeloma patients. Br J Haematol. 2021;192(6):1064\u20137. https:\/\/doi.org\/10.1111\/bjh.16673.","journal-title":"Br J Haematol"},{"issue":"7","key":"990_CR19","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s00277-021-04529-5","volume":"100","author":"MJ Cejalvo","year":"2021","unstructured":"Cejalvo MJ, Bustamante G, Gonz\u00e1lez E, V\u00e1zquez-\u00c1lvarez J, Garc\u00eda R, Ram\u00edrez-Payer \u00c1, et al. Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma. Ann Hematol. 2021;100(7):1769\u201378. https:\/\/doi.org\/10.1007\/s00277-021-04529-5.","journal-title":"Ann Hematol"},{"issue":"26","key":"990_CR20","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.2217\/fon-2021-0301","volume":"17","author":"J\u00c1 Hern\u00e1ndez-Rivas","year":"2021","unstructured":"Hern\u00e1ndez-Rivas J\u00c1, Arnao M, Argui\u00f1ano P\u00e9rez JM, Rubio A, Garc\u00eda EG, de Miguel D, et al. Treatment patterns and outcomes among nontransplant newly diagnosed multiple myeloma patients in Spain. Future Oncol. 2021;17(26):3465\u201376. https:\/\/doi.org\/10.2217\/fon-2021-0301.","journal-title":"Future Oncol"},{"issue":"5","key":"990_CR21","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122\u20138. https:\/\/doi.org\/10.1038\/leu.2013.313.","journal-title":"Leukemia"},{"issue":"3","key":"990_CR22","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/ejh.13439","volume":"105","author":"M Mohty","year":"2020","unstructured":"Mohty M, Knauf W, Romanus D, Corman S, Verleger K, Kwon Y, et al. Real-world treatment patterns and outcomes in non-transplant newly diagnosed multiple myeloma in France, Germany, Italy, and the United Kingdom. Eur J Haematol. 2020;105(3):308\u201325. https:\/\/doi.org\/10.1111\/ejh.13439.","journal-title":"Eur J Haematol"},{"issue":"3","key":"990_CR23","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00277-016-2888-3","volume":"96","author":"A Berenson","year":"2017","unstructured":"Berenson A, Vardanyan S, David M, Wang J, Harutyunyan NM, Gottlieb J, et al. Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic. Ann Hematol. 2017;96(3):441\u20138. https:\/\/doi.org\/10.1007\/s00277-016-2888-3.","journal-title":"Ann Hematol"},{"issue":"2","key":"990_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/ejh.13707","volume":"108","author":"CH Blimark","year":"2022","unstructured":"Blimark CH, Vangsted AJ, Klausen TW, Gregersen H, Szabo AG, Hermansen E, et al. Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries. Eur J Haematol. 2022;108(2):99\u2013108. https:\/\/doi.org\/10.1111\/ejh.13707.","journal-title":"Eur J Haematol"},{"issue":"1","key":"990_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/cam4.2656","volume":"9","author":"S Ailawadhi","year":"2020","unstructured":"Ailawadhi S, Jagannath S, Narang M, Rifkin RM, Terebelo HR, Toomey K, et al. Connect MM Registry as a national reference for United States multiple myeloma patients. Cancer Med. 2020;9(1):35\u201342. https:\/\/doi.org\/10.1002\/cam4.2656.","journal-title":"Cancer Med"},{"issue":"23","key":"990_CR26","doi-asserted-by":"publisher","first-page":"7073","DOI":"10.1158\/1078-0432.CCR-07-0527","volume":"13","author":"J Haessler","year":"2017","unstructured":"Haessler J, Shaughnessy JD Jr, Zhan F, Crowley J, Epstein J, van Rhee F, et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res. 2017;13(23):7073\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0527.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"990_CR27","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/leu.2013.220","volume":"28","author":"S Lonial","year":"2014","unstructured":"Lonial S, Anderson KC. Association of response endpoints with survival outcomes in multiple myeloma. Leukemia. 2014;28(2):258\u201368. https:\/\/doi.org\/10.1038\/leu.2013.220.","journal-title":"Leukemia"},{"issue":"11","key":"990_CR28","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","volume":"117","author":"F Gay","year":"2011","unstructured":"Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood. 2011;117(11):3025\u201331. https:\/\/doi.org\/10.1182\/blood-2010-09-307645.","journal-title":"Blood"},{"issue":"6","key":"990_CR29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/ejh.12868","volume":"98","author":"M Mainou","year":"2017","unstructured":"Mainou M, Madenidou AV, Liakos A, Paschos P, Karagiannis T, Bekiari E, et al. Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis. Eur J Haematol. 2017;98(6):563\u20138. https:\/\/doi.org\/10.1111\/ejh.12868.","journal-title":"Eur J Haematol"},{"issue":"1","key":"990_CR30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41408-023-00803-z","volume":"13","author":"S Noori","year":"2023","unstructured":"Noori S, Wijnands C, Langerhorst P, Bonifay V, Stingl C, Touzeau C, et al. Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry. Blood Cancer J. 2023;13(1):30. https:\/\/doi.org\/10.1038\/s41408-023-00803-z.","journal-title":"Blood Cancer J"},{"issue":"2","key":"990_CR31","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/leu.2013.217","volume":"28","author":"N Puig","year":"2014","unstructured":"Puig N, Sarasquete ME, Balanzategui A, Mart\u00ednez J, Paiva B, Garc\u00eda H, et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia. 2014;28(2):391\u20137. https:\/\/doi.org\/10.1038\/leu.2013.217.","journal-title":"Leukemia"},{"issue":"23","key":"990_CR32","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4(23):5988\u201399. https:\/\/doi.org\/10.1182\/bloodadvances.2020002827.","journal-title":"Blood Adv"},{"issue":"1","key":"990_CR33","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1016\/j.clml.2022.10.008","volume":"23","author":"DM Foureau","year":"2023","unstructured":"Foureau DM, Paul BA, Guo F, Lipford EH, Fesenkova K, Tjaden E, et al. Standardizing clinical workflow for assessing minimal residual disease by flow cytometry in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2023;23(1):e41\u201350. https:\/\/doi.org\/10.1016\/j.clml.2022.10.008.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"17","key":"990_CR34","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1200\/JCO.19.02515","volume":"38","author":"NS Joseph","year":"2020","unstructured":"Joseph NS, Kaufman JL, Dhodapkar MV, Hofmeister CC, Almaula DK, Heffner LT, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol. 2020;38(17):1928\u201337. https:\/\/doi.org\/10.1200\/JCO.19.02515.","journal-title":"J Clin Oncol"},{"issue":"14","key":"990_CR35","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1611750.","journal-title":"N Engl J Med"},{"issue":"2","key":"990_CR36","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387(2):132\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2204925.","journal-title":"N Engl J Med"},{"issue":"12","key":"990_CR37","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s41408-022-00757-8","volume":"12","author":"S Goldman-Mazur","year":"2022","unstructured":"Goldman-Mazur S, Visram A, Rajkumar SV, Kapoor P, Dispenzieri A, Lacy MQ, et al. Second- and third-line treatment strategies in multiple myeloma: a referral-center experience. Blood Cancer J. 2022;12(12):164. https:\/\/doi.org\/10.1038\/s41408-022-00757-8.","journal-title":"Blood Cancer J"},{"issue":"10218","key":"990_CR38","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","volume":"395","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020;395(10218):132\u201341. https:\/\/doi.org\/10.1016\/S0140-6736(19)32956-3.","journal-title":"Lancet"},{"issue":"8","key":"990_CR39","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936\u201345. https:\/\/doi.org\/10.1182\/blood.2020005288.","journal-title":"Blood"},{"issue":"10292","key":"990_CR40","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","volume":"397","author":"P Moreau","year":"2021","unstructured":"Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397(10292):2361\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(21)00592-4.","journal-title":"Lancet"},{"issue":"11","key":"990_CR41","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41408-018-0141-0","volume":"8","author":"PG Richardson","year":"2018","unstructured":"Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018;8(11):109. https:\/\/doi.org\/10.1038\/s41408-018-0141-0.","journal-title":"Blood Cancer J"},{"issue":"2","key":"990_CR42","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/ejh.13426","volume":"105","author":"G Afram","year":"2020","unstructured":"Afram G, Gran C, Borg Bruchfeld J, Wagner AK, Hussain A, Alici E, et al. Impact of performance status on overall survival in patients with relapsed and\/or refractory multiple myeloma: real-life outcomes of daratumumab treatment. Eur J Haematol. 2020;105(2):196\u2013202. https:\/\/doi.org\/10.1111\/ejh.13426.","journal-title":"Eur J Haematol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-00990-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-023-00990-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-00990-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T09:18:32Z","timestamp":1695460712000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-023-00990-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["990"],"URL":"https:\/\/doi.org\/10.1007\/s11523-023-00990-6","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"9 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"JRB designed the study and RS collected specimens for analysis. SB, BR, ME-S, BE, and SE generated the data. SJ organized and analyzed the data. SJ, SK and JRB wrote the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"James R. Berenson has equity interests in ONCOtracker. Scott Jew, Sean Bujarski, Bernard Regidor, Marsiye Emamy-Sadr, Regina Swift, Benjamin Eades, Susanna Kim, and Shahrooz Eshaghian have no conflicts of interest to declare that might be relevant to the contents of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All patients provided informed consent and this study was approved by the Institutional Review Board or independent Ethics Committee of each study site, in accordance with their requirements and the Declaration of Helsinki.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All study participants completed a written consent form indicating their understanding of the provided study information and the opportunity to ask questions.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"By providing consent for publication, all involved parties acknowledge their understanding that the study findings, results, or related data may be utilized in academic journals, conference presentations, or online platforms.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statements"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}